X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (56) 56
index medicus (42) 42
male (40) 40
female (39) 39
aged (37) 37
dermatology (37) 37
middle aged (35) 35
adult (32) 32
skin neoplasms - pathology (27) 27
melanoma (25) 25
aged, 80 and over (22) 22
abridged index medicus (15) 15
care and treatment (15) 15
cancer (14) 14
retrospective studies (14) 14
risk factors (14) 14
follow-up studies (13) 13
life sciences (13) 13
prognosis (12) 12
survival (12) 12
melanoma - pathology (11) 11
oncology (11) 11
skin neoplasms - drug therapy (11) 11
skin neoplasms - genetics (11) 11
chemotherapy (9) 9
neoplasm staging (9) 9
prospective studies (9) 9
t-cell lymphoma (9) 9
diagnosis (8) 8
melanoma - genetics (8) 8
skin neoplasms - mortality (8) 8
time factors (8) 8
metastasis (7) 7
mutation (7) 7
patients (7) 7
research (7) 7
skin (7) 7
skin neoplasms - diagnosis (7) 7
tumors (7) 7
[ sdv.can ] life sciences [q-bio]/cancer (6) 6
adolescent (6) 6
elderly-patients (6) 6
expression (6) 6
france (6) 6
france - epidemiology (6) 6
immunohistochemistry (6) 6
incidence (6) 6
leg (6) 6
medicine & public health (6) 6
melanoma - drug therapy (6) 6
pathology (6) 6
prognostic-factors (6) 6
skin neoplasms - epidemiology (6) 6
survival rate (6) 6
therapy (6) 6
treatment outcome (6) 6
who-eortc classification (6) 6
young adult (6) 6
analysis (5) 5
child (5) 5
clinical trials (5) 5
complications and side effects (5) 5
cutaneous malignant-melanoma (5) 5
genetic predisposition to disease (5) 5
health aspects (5) 5
lymphoma, large b-cell, diffuse - pathology (5) 5
lymphomas (5) 5
malignant-melanoma (5) 5
management (5) 5
melanoma - epidemiology (5) 5
metastases (5) 5
mycosis-fungoides (5) 5
pembrolizumab (5) 5
risk-factors (5) 5
studies (5) 5
treatment-of-cancer (5) 5
age factors (4) 4
antibodies, monoclonal - therapeutic use (4) 4
biopsy (4) 4
bullous pemphigoid (4) 4
cancer therapies (4) 4
disease (4) 4
guidelines (4) 4
hematology (4) 4
ipilimumab (4) 4
lesions (4) 4
lymphoma, t-cell, cutaneous - pathology (4) 4
medicine, general & internal (4) 4
melanoma - mortality (4) 4
melanoma - secondary (4) 4
metastatic melanoma (4) 4
mycosis fungoides (4) 4
patient outcomes (4) 4
pemphigoid, bullous - immunology (4) 4
risk (4) 4
sex factors (4) 4
skin neoplasms - metabolism (4) 4
skin neoplasms - therapy (4) 4
surgery (4) 4
surveys and questionnaires (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
by Kamilia, Chtara and Regaieg, Kais and Baccouch, Najeh and Chelly, Hedi and Bahloul, Mabrouk and Bouaziz, Mounir and Jendoubi, Ali and Abbes, Ahmed and Belhaouane, Houda and Nasri, Oussama and Jenzri, Layla and Ghedira, Salma and Houissa, Mohamed and Belkadi, Kamal and Harti, Youness and Nsiri, Afak and Khaleq, Khalid and Hamoudi, Driss and Harrar, Rachid and Thieffry, Camille and Wallet, Frédéric and Parmentier-Decrucq, Erika and Favory, Raphaël and Mathieu, Daniel and Poissy, Julien and Lafon, Thomas and Vignon, Philippe and Begot, Emmanuelle and Appert, Alexandra and Hadj, Mathilde and Claverie, Paul and Matt, Morgan and Barraud, Olivier and François, Bruno and Jamoussi, Amira and Jazia, Amira Ben and Marhbène, Takoua and Lakhdhar, Dhouha and Khelil, Jalila Ben and Besbes, Mohamed and Goutay, Julien and Blazejewski, Caroline and Joly-Durand, Isabelle and Pirlet, Isabelle and Weillaert, Marie Pierre and Beague, Sebastien and Aziz, Soufi and Hafiane, Reda and Hattabi, Khalid and Bouhouri, Mohamed Aziz and Hammoudi, Driss and Fadil, Abdelaziz and Harrar, Rachid Al and Zerouali, Khalid and Medhioub, Fatma Kaaniche and Allela, Rania and Algia, Najla Ben and Cherif, Samar and Slaoui, Mohamed Taoufik and Boubia, Souhail and Hafiani, Y and Khaoudi, A and Cherkab, R and Elallam, W and Elkettani, C and Barrou, L and Ridaii, M and Mehdi, Rihi El and Schimpf, Caroline and Mizrahi, Assaf and Pilmis, Benoît and Le Monnier, Alban and Tiercelet, Kelly and Cherin, Mélanie and Bruel, Cédric and Philippart, Francois and Bailly, Sébastien and Lucet, Jc and Lepape, Alain and L’hériteau, François and Aupée, Martine and Bervas, Caroline and Boussat, Sandrine and Berger-Carbonne, Anne and Machut, Anaïs and Savey, Anne and Timsit, Jean-François and Razazi, Keyvan and Rosman, Jérémy and de Prost, Nicolas and Carteaux, Guillaume and Jansen, Chloe and Decousser, Jean Winoc and Brun-Buisson, Christian and Dessap, Armand Mekontso and M’rad, Aymen and Ouali, Zouhour and Barghouth, Manel and Kouatchet, Achille and Mahieu, Rafael and ... and REA‑RAISIN Study group and Clinical Research in Intensive Care and Sepsis (CRICS network) and Sudden Death Expertise Center and OUTCOMEREA study group and Brain Liver Pitié-Salpêtrière Study Group (BLIPS) and for the HYPER2S Investigators and REVA research network and Cubrea network
Annals of Intensive Care, ISSN 2110-5820, 1/2017, Volume 7, Issue S1, pp. 105 - 207
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 1, pp. 30 - 39
In patients with melanomas containing activating BRAF mutations, the combination of a BRAF inhibitor and a MEK inhibitor improved overall survival, as compared... 
CRITERIA | BRAF-MUTATED MELANOMA | METASTATIC MELANOMA | RAF INHIBITION | MEDICINE, GENERAL & INTERNAL | MEK INHIBITION | ACQUIRED-RESISTANCE | V600E MUTATION | TUMORS | OVERCOME | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10094, pp. 555 - 566
Journal Article
Journal Article
by Jaillette, Emmanuelle and Girault, Christophe and Brunin, Guillaume and Zerimech, Farid and Chiche, Arnaud and Broucqsault-Dedrie, Céline and Fayolle, Cyril and Minacori, Franck and Alves, Isabelle and Barrailler, Stephanie and Robriquet, Laurent and Delaporte, Emmanuel and Thellier, Damien and Delcourte, Claire and Duhamel, Alain and Nseir, Saad and Valette, Xavier and Desmeulles, Isabelle and Savary, Benoit and Masson, Romain and Seguin, Amélie and Daubin, Cédric and Sauneuf, Bertrand and Verrier, Pierre and Pottier, Véronique and Orabona, Marie and Samba, Désiré and Viquesnel, Gérald and Lermuzeaux, Mathilde and Hazera, Pascal and Hanouz, Jean-Luc and Parienti, Jean-Jacques and Du Cheyron, Damien and Demoule, Alexandre and Clavel, Marc and Rolland-Debord, Camille and Perbet, Sébastien and Terzi, Nicolas and Kouatchet, Achille and Wallet, Florent and Roze, Hadrien and Vargas, Frédéric and Guérin, Claude and Dellamonica, Jean and Jaber, Samir and Similowski, Thomas and Quenot, Jean-Pierre and Binquet, Christine and Vinsonneau, Christophe and Barbar, Saber-Davide and Vinault, Sandrine and Deckert, Valérie and Lemaire, Stephanie and Hssain, Ali Ait and Bruyère, Rémi and Souweine, Bertrand and Lagrost, Laurent and Adrie, Christophe and Jung, Boris and Daurat, Aurelien and De Jong, Audrey and Chanques, Gérald and Mahul, Martin and Monnin, Marion and Molinari, Nicolas and Lheureux, Olivier and Trepo, Eric and Hites, Maya and Cotton, Frederic and Wolff, Fleur and Surin, Rudy and Créteur, Jacques and Vincent, Jean-Louis and Gustot, Thierry and Jacobs, Frederique and Taccone, Fabio Silvio and Neuville, Mathilde and Timsit, Jean-François and El-Helali, Najoua and Le Monnier, Alban and Magalhaes, Eric and Radjou, Aguila and Smonig, Roland and Soubirou, Jean-François and Voiriot, Guillaume and Sonneville, Romain and Bouadma, Lila and Mourvillier, Bruno and Gélisse, Elodie and Brasseur, Alexandre and Roisin, Sandrine and De Backer, Daniel and Van Ruychevelt, Valerie and Carlier, Eric and Piagnerelli, Michael and Vanhaeverbeek, Michel and Danguy, Christine and Biston, Patrick and Au, Siu-Ming and Begot, Emmanuelle and ... and Qualité et Sécurité des Soins - CBPR-CFAR and Brain Liver Pitié-Salpêtrière Study Group (BLIPS), Paris, France and Working Group on Mechanical Ventilation and Outcomerea Study Group and COCOONs Study Group and Groupe ALIVE and For the GrrrOH: Groupe de recherche en réanimation respiratoire en Onco-Hématologie (Group for Research in Respiratory Intensive Care Onco-Hematology and EPURE Study Group and For the OUTCOMEREA Study Group and For the BIBLIOFLASH Study Group and Groupe de Recherche en Réanimation Respiratoire et Onco-Hematologique (GRRROH) and RETROMARS Study Group and BoReal study group and ABDOMIX Group and Groupe de travail sur la ventilation and Groupe de Recherche en Reanimation Respiratoire du patient d’Onc-hématologie and Groupe RMM and Université Paris 6 —Pierre et Marie Curie and Institut National pour la Santé et la Recherche Médicale, UMRS1158, Paris and Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie and ABLE French Investigators and ENCEPHALITICA Study Group and Septiflux trial Group and CRICS Network and OutcomeRéa and Committee of young intensivists of the French Society for Intensive Care Medicine (FICS) and NutriSIP and CNER DESC réanimation grand ouest and Phase Angle Project Investigators
Annals of Intensive Care, ISSN 2110-5820, 6/2016, Volume 6, Issue S1, pp. 1 - 236
PHYSICIANS ABSTRACTSO1 Impact of tracheal cuff shape on microaspiration of gastric contents in intubated critically ill patients: a multicenter randomized... 
Intensive / Critical Care Medicine | Emergency Medicine | Anesthesiology | Medicine & Public Health
Journal Article